ABSTRACT

This study's objective is to offer an in-depth overview of the various analytical procedures used to determine Teneligliptin Hydrobromide Hydrate, Metformin Hydrochloride, Pioglitazone Hydrochloride, and their combinations in marketed formulations. This study contains UV, RP- HPLC, TLC, and other procedures that have been reported to date. Teneligliptin Hydrobromide Hydrate is approved as monotherapy or with other oral hypoglycaemic medicines (e.g., metformin, pioglitazone, sulfonylureas, glinides, and glucosidase inhibitors). Pioglitazone Hydrochloride is a thiazolidinedione that improves the body's sensitivity to insulin. Metformin Hydrochloride is a biguanide that reduces sugar production and absorption in your body while improving the usage of current insulin. They work in tandem to improve blood sugar control. This review summarizes the studies done on the medications indicated above, either alone or in combination with or without the presence of contaminants. Keywords: Anti- diabetic, Teneligliptin Hydrobromide Hydrate, Metformin Hydrochloride, HPLC, UV
Publication date: 01/10/2024

https://ijbpas.com/pdf/2024/October/MS_IJBPAS_2024_8397.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2024/13.10.8397